QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: How to Read an EMA Referral From a Pharmacovigilance Perspective

Test your understanding of the concepts covered by How to Read an EMA Referral From a Pharmacovigilance Perspective.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the main value of comparing the initial notification with the final recommendation?

It shows how the regulatory question and level of certainty evolved as evidence accumulated It proves that the initial concern was already the final conclusion It eliminates the need to read the assessment report It allows later evidence to be treated as though it was available at initiation

Question 2 of 10 What does biological or pharmacological plausibility contribute to a safety assessment?

It can support a causal hypothesis but does not by itself establish clinical frequency or significance It establishes the incidence of the adverse event It replaces the need for clinical and epidemiological evidence It proves that every exposed patient is at risk

Question 3 of 10 Which reading strategy is most useful when time is limited but a professional understanding of the referral is required?

Read only the newest document Start with the notification, list of questions, assessment report and final decision Read only the package leaflet Count the number of supporting studies in the bibliography

Question 4 of 10 Why should evidence from individual case reports, clinical trials and epidemiological studies not be treated as interchangeable?

They provide different types of information and have different strengths and limitations Only clinical trials can ever contribute to causality assessment Case reports are always more reliable than comparative studies Epidemiological studies are used only after a legal decision

Question 5 of 10 Which pattern would most strongly support increased confidence in a suspected drug-event relationship?

A single report with incomplete timing and several alternative causes Consistent clinical phenotype, compatible timing, comparative association, exposure-response and biological plausibility A large number of publications without checking for duplication or quality A positive mechanistic experiment without clinical observations

Question 6 of 10 Why is a statistically significant association in an epidemiological study not automatically equivalent to proof of causation?

The association may reflect confounding, bias, exposure misclassification or other methodological limitations Statistical significance is irrelevant to all regulatory assessments Causality can only be established through mechanistic studies A significant association always indicates a reporting error

Question 7 of 10 Why should absolute risk be considered alongside relative risk in a referral assessment?

Relative risk is never useful in regulatory work A large relative increase may represent a small absolute excess, while a modest relative increase may affect many patients when exposure is widespread Absolute risk can be calculated from spontaneous report counts alone Absolute risk determines causality independently of study design

Question 8 of 10 What does initiation of an EMA referral generally demonstrate about a safety concern?

That causality has been definitively established That a formal EU-level assessment is considered necessary That the marketing authorisation must be suspended That the suspected event has a known incidence rate

Question 9 of 10 Why should evidence against a safety hypothesis be actively examined during referral analysis?

It helps determine how conflicting information and residual uncertainty were weighed It is required only when the referral is likely to end in withdrawal Negative evidence automatically invalidates all positive evidence It prevents regulators from considering serious outcomes

Question 10 of 10 What is the most appropriate conclusion from a negative clinical trial regarding a very rare serious adverse event?

The risk is definitively absent The trial may not have been sufficiently powered to exclude the risk The event must be unrelated to the medicine The trial result should always outweigh all other evidence

QPPV.com

Knowledge Assessment: How to Read an EMA Referral From a Pharmacovigilance Perspective

Cookie Settings